Multi-dose tirzepatide presentations get their own 30-day in-use window, splitting the storage answer by device

Storage instructions for tirzepatide, sold as Zepbound and Mounjaro, now split by device type. FDA records for Zepbound's approved application, NDA 217806, show a series of labeling supplements filed through 2026, including a container and package insert update dated January 20, 2026, and further labeling changes in February and August 2026 ^[1]. Those updates are the basis for a change that pharmacists and patients are starting to notice: the multi-dose vial and the KwikPen now carry their own 30-day in-use limit, separate from the 21-day limit that has applied to single-dose pens and vials since Mounjaro's original approval in 2022 ^[1].

The Zepbound product line approved under NDA 217806 includes single-dose vials and single-dose autoinjector pens in 0.5 mL fill sizes, covering doses from 2.5 mg up to 15 mg, and separately a set of KwikPen and larger-volume vial presentations in 2.4 mL fills, covering doses from 10 mg up to 60 mg ^[1]. The 2.4 mL size is large enough to hold more than one weekly dose, which is why it is treated differently for storage purposes than the smaller single-dose containers.

Under the newer labeling, a multi-dose vial or KwikPen is meant to be discarded 30 days after it is first used at room temperature, or after four weekly doses have been withdrawn, whichever happens first ^[1]. That is a different rule from the single-dose pens and vials, which keep the 21-day room-temperature window that has been part of tirzepatide labeling since Mounjaro's 2022 approval and did not change with the 2026 supplements ^[1].

The practical effect is that the same question, how long can this pen sit on the counter, now has two different correct answers depending on which product a pharmacy dispensed. A single-dose Zepbound pen or vial still follows the 21-day rule. A KwikPen or multi-dose vial follows the newer 30-day, four-dose rule.

Why it matters for patients

Storage questions are among the most common things patients ask about GLP-1 medicines, largely because a pen that has been left out too long or used past its window may not be safe or fully effective. Because tirzepatide is now sold in both single-dose and multi-dose formats under the Zepbound brand, patients and caregivers need to check which device their prescription actually names before applying a storage rule. A label or pharmacy printout that just says "tirzepatide" is not enough information on its own; the difference between 21 days and 30 days, and between a per-vial count and a per-dose count, depends on the specific product dispensed ^[1].

This also matters for people who split a multi-dose vial or KwikPen across several weekly injections. The four-dose cap means that even if 30 days have not passed, the device should still be discarded once four weekly doses have been drawn from it ^[1]. Tracking both the calendar date of first use and the number of doses taken is now part of using these multi-dose presentations correctly.

What happens next

FDA records show tirzepatide labeling has continued to be updated through 2026, with supplements filed in January, February, and August of that year ^[1]. It is not yet known from the available records whether further storage changes are planned, or whether Lilly will publish a single consolidated chart covering all three device types. Patients with questions about a specific pen or vial should check the printed labeling that comes with their own prescription, since it reflects the version in effect for that lot.